Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00684021
First received: May 22, 2008
Last updated: April 2, 2013
Last verified: April 2013
Results First Received: January 18, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Left Ventricular Dysfunction
Interventions: Biological: Adult stem cells
Biological: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment took place at five Network centers and their associated satellite facilities between July 2008 and November 2011. The main centers are located in Ohio, Texas, Florida, Minnesota, and Tennessee. Study brochures, patient informational DVDs, and clinical trials.gov were among the tools used for recruitment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Day 3 Stem Cell Arm Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
Day 3 Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
Day 7 Stem Cell Arm Participants will receive active adult stem cell infusion 7 days after PCI.
Day 7 Placebo Arm Participants will receive placebo infusion (5% HSA) 7 days after PCI.

Participant Flow:   Overall Study
    Day 3 Stem Cell Arm     Day 3 Placebo Arm     Day 7 Stem Cell Arm     Day 7 Placebo Arm  
STARTED     43     24     36     17  
COMPLETED     41     22     34     15  
NOT COMPLETED     2     2     2     2  
MRI Contraindicated                 1                 1                 1                 0  
MRI not performed                 0                 1                 1                 2  
Death                 1                 0                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Day 3 Stem Cell Arm Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
Day 3 Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
Day 7 Stem Cell Arm Participants will receive active adult stem cell infusion 7 days after PCI.
Day 7 Placebo Arm Participants will receive placebo infusion (5% HSA) 7 days after PCI.
Total Total of all reporting groups

Baseline Measures
    Day 3 Stem Cell Arm     Day 3 Placebo Arm     Day 7 Stem Cell Arm     Day 7 Placebo Arm     Total  
Number of Participants  
[units: participants]
  43     24     36     17     120  
Age  
[units: years]
Mean ± Standard Deviation
  55.6  ± 10.8     57.0  ± 12.4     58.2  ± 11.3     57.0  ± 8.0     56.9  ± 10.9  
Gender  
[units: participants]
         
Female     5     3     5     2     15  
Male     38     21     31     15     105  
Region of Enrollment  
[units: participants]
         
United States     43     24     36     17     120  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Global Left Ventricular Function   [ Time Frame: Measured at Baseline and Month 6 ]

2.  Primary:   Regional Left Ventricular Function (Infarct Zone Wall Motion)   [ Time Frame: Measured at Baseline and Month 6 ]

3.  Primary:   Regional Left Ventricular Function (Border Zone Wall Motion)   [ Time Frame: Measured at Baseline and Month 6 ]

4.  Secondary:   Clincal and Safety Outcomes   [ Time Frame: Measured from baseline to six months. ]

5.  Secondary:   Left Ventricular Mass   [ Time Frame: Measured at Baseline and Month 6 ]

6.  Secondary:   End Diastolic Volume Index   [ Time Frame: Measured at Baseline and Month 6 ]

7.  Secondary:   End Systolic Volume Index   [ Time Frame: Measured at Baseline and Month 6 ]

8.  Secondary:   Infarct Volume   [ Time Frame: Measured at Baseline and Month 6 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Events reported are from Randomization Date to the 6 month endpoint data collection window (i.e. 210 days post intervention)
Additional Description No text entered.

Reporting Groups
  Description
Day 3 Stem Cell Arm Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
Day 3 Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
Day 7 Stem Cell Arm Participants will receive active adult stem cell infusion 7 days after PCI.
Day 7 Placebo Arm Participants will receive placebo infusion (5% HSA) 7 days after PCI.

Serious Adverse Events
    Day 3 Stem Cell Arm     Day 3 Placebo Arm     Day 7 Stem Cell Arm     Day 7 Placebo Arm  
Total, serious adverse events          
# participants affected / at risk     17/43 (39.53%)     6/24 (25.00%)     11/36 (30.56%)     2/17 (11.76%)  
Cardiac disorders          
Chest Pain        
# participants affected / at risk     8/43 (18.60%)     2/24 (8.33%)     1/36 (2.78%)     0/17 (0.00%)  
# events     9     2     1     0  
Angina        
# participants affected / at risk     2/43 (4.65%)     0/24 (0.00%)     2/36 (5.56%)     0/17 (0.00%)  
# events     2     0     2     0  
Heart Failure        
# participants affected / at risk     4/43 (9.30%)     1/24 (4.17%)     0/36 (0.00%)     0/17 (0.00%)  
# events     4     1     0     0  
New/Worsening Thrombus        
# participants affected / at risk     1/43 (2.33%)     2/24 (8.33%)     5/36 (13.89%)     1/17 (5.88%)  
# events     1     2     5     1  
Coronary Artery Disease        
# participants affected / at risk     1/43 (2.33%)     0/24 (0.00%)     2/36 (5.56%)     0/17 (0.00%)  
# events     1     0     2     0  
Cardiomyopathy        
# participants affected / at risk     1/43 (2.33%)     1/24 (4.17%)     1/36 (2.78%)     1/17 (5.88%)  
# events     1     1     1     1  
Events were collected by systematic assessment




  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The choice of Day 3 or Day 7 as randomization points while based on the literature were nevertheless somewhat arbitrary. cMR-baseed ejection fractions tended to be high.  


Results Point of Contact:  
Name/Title: Lemuel Moye, MD, PhD
Organization: UT-Houston School of Public Health
phone: 713-500-9518
e-mail: Lemmoye@msn.com


Publications of Results:
Other Publications:
Publications automatically indexed to this study:

Responsible Party: Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00684021     History of Changes
Other Study ID Numbers: 579, U01HL087318, 1 U01-HL-087318-01 (Project 1)
Study First Received: May 22, 2008
Results First Received: January 18, 2013
Last Updated: April 2, 2013
Health Authority: United States: Food and Drug Administration